
    
      Zolpidem will be used as an active intervention to assess the sensitivity to change of IDSIQ™
      in patients suffering from insomnia disorder.

      IDSIQ™ will be administered during the screening period (within 14 days before enrollment in
      the study) and the treatment period (from Day 1 to Day 14). End of study (phone call) will
      take place 30-37 days after the end-of-treatment.
    
  